Vue transversale globale
Toutes les maladies
Un même point d’entrée pour les études cliniques, les découvertes scientifiques, les publications et les pistes exploratoires présentes dans Biomedical Watch.
Périmètre
Filtrer toute la vue
Chaque choix s’applique immédiatement aux quatre sections. Le filtre « type de SEP » n’apparaît que lorsque la sclérose en plaques est sélectionnée.
8666 résultats correspondants
· 41 visibles sur cette page
dans le périmètre Toutes les maladies
Niveau clinique
Études et traitements 4050
Interventions, programmes et essais cliniques rattachés au périmètre sélectionné.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| anti-CD19-CAR-T cells NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refra… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an investigator-initiated trial to evaluate the safety and efficac… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ASP2802 NCT06248086 · A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell L… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | TERMINATED | CAR-T cell therapy is a type of treatment for people with certain lymphoma… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Bexxar NCT00434629 · Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Ce… | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | Patients with B-cell lymphoma who relapse after autologous transplant tend… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CD19/CD22 CAR-T NCT04499573 · Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B… | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | ACTIVE_NOT_RECRUITING | The purpose of this study is to evaluate the safety and efficiency of auto… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| cemacabtagene ansegedleucel NCT06500273 · ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients Wi… | Sclérose en plaques | À vérifier | Phase 2 | RECRUITING | This is a randomized, open-label study in adult patients who have complete… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Deplet… NCT03810196 · CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Non applicable | RECRUITING | The major morbidities of allogeneic hematopoietic stem cell transplant wit… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy NCT06590545 · IDEAL — Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis | Sclérose en plaques | Thérapie cellulaire | Phase 1/2 | NOT_YET_RECRUITING | The goal of this phase I/II clinical trial is to investigate anti-CD 19 ch… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rapcabtagene autoleucel (YTB323) NCT07443137 · CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study) | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | NOT_YET_RECRUITING | This is an open-label, multi-center, non-confirmatory study to assess the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| rondecabtagene autoleucel NCT07188558 · PiNACLE-H2H — A Study to Investigate Ronde-cel Versus Investigator's Choice CD19… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 3 | RECRUITING | This Phase 3 study compares rondecabtagene autoleucel (ronde-cel), a dual-… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| TC011 single-arm NCT07360288 · TC011_FL_201 — Efficacy and Safety of TC011 in Relapsed or Refractory Follicular… | Sclérose en plaques | Thérapie cellulaire | Phase 2 | NOT_YET_RECRUITING | This Phase II, multi-center, single-arm, open-label study evaluates the ef… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| ThisCART19A with Dose Level 1 NCT05691153 · ThisCART19A for B-NHL Relapsed After Auto-CAR T | Sclérose en plaques | Thérapie cellulaire | Phase 1 | UNKNOWN | This is a phase 1, single-center, dose selection study to evaluate the eff… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:27 | Détail |
| Rituximab NCT03636503 · Rituximab + Immunotherapy in Follicular Lymphoma | Sclérose en plaques | À vérifier | Phase 1 | TERMINATED | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Rituximab NCT00006669 · Rituximab Followed by Combination Chemotherapy in Treating Patients With Refract… | Sclérose en plaques | À vérifier | Phase 2 | WITHDRAWN | The primary objective of this phase III trial is to investigate if Rituxim… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| SCT400 plus CHOP NCT02772822 · A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxyd… | Sclérose en plaques | Immunomodulation | Phase 3 | UNKNOWN | The primary objective of the study is to assess the efficiency of SCT400 p… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:26 | Détail |
| Armored and GPC3-targeted autologous CAR T-cell NCT06590246 · A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocell… | Sclérose en plaques | À vérifier | Phase 1/2 | RECRUITING | This single-arm, open-label multicenter Phase I/II study will evaluate the… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT05155189 · A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031… | Sclérose en plaques | Immunomodulation · Thérapie cellulaire | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| C-CAR031 NCT07444281 · An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Ad… | Sclérose en plaques | À vérifier | Phase 1 | RECRUITING | A study that aimed to assess the safety and anti-tumor activity of CCAR031… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| CD19/CD20-directed Chimeric Antigen Receptor T Cells NCT05149391 · A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgk… | Sclérose en plaques | Immunomodulation | Phase 1 | COMPLETED | This is a single-center, open-label study to evaluate the safety and effic… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04317885 · A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects | Sclérose en plaques | À vérifier | Phase 1 | COMPLETED | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
| Prizloncabtagene Autoleucel NCT04693676 · A Study of C-CAR039 Treatment in Subjects With r/r NHL Subjects Non-Hodgkin's Ly… | Sclérose en plaques | À vérifier | Phase 1 | UNKNOWN | The trial is a single arm, single-center, non-randomized phase I clinical… À vérifier | ClinicalTrials.gov 2026-09-20 04:37:25 | Détail |
Découverte scientifique
Recherches et trouvailles 21
Projets précliniques, publications émergentes et programmes de recherche suivis dans le pipeline.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| 4-octyl itaconate et dérivés Dérivés de l’itaconate — neuroinflammation | Sclérose latérale amyotrophique | Neuroprotection · Immunomodulation | Découverte fondamentale | Exploratoire | Modulation immunométabolique de la microglie · NRF2 / inflammation microgl… Piste mécanistique visant à reprogrammer la réponse inflammatoire de la microglie. Le lien avec la SLA reste exploratoi… | Revue scientifique 2024-07-01 | Détail |
Bibliographie
Publications 4595
Références bibliographiques de la base locale et accès à leur source originale.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Immune Spatial Organization Predicts Distant Metastasis Risk in Aggre… Abiraterone acetate · PMID 42113020 | Cancer | Immunomodulation | Publication | PubMed | Voir la publication source Computational pathology has emerged as an attractive option for improving risk stratification in prostate cancer, but m… | Clinical cancer research : an official journal of the… 2026-08-16 13:17:42 | Source |
| Metabolic Dysfunction After Initiation of Androgen Receptor Pathway I… Abiraterone acetate · PMID 42593785 | Hypertension artérielle · Cancer | À vérifier | Publication | PubMed | Voir la publication source Metabolic syndrome (MetS) includes obesity, insulin resistance, hypertension, and dyslipidemia. While androgen deprivat… | JAMA oncology 2026-08-16 13:17:42 | Source |
| Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN d… Abiraterone acetate · PMID 42359636 | Cancer | Ralentissement de la progression | Publication | PubMed | Voir la publication source Loss of the tumor suppressor gene is a common molecular feature in advanced prostate cancer and is associated with acti… | Cancer biology & therapy 2026-08-16 13:17:42 | Source |
| The association between pubertal timing and diurnal cortisol activity… Hydrocortisone · PMID 42603154 | Cancer · Sclérose en plaques · Cancer | Thérapie génique | Publication | PubMed | Voir la publication source The pubertal development stage is associated with mental health. One explanation is that the pubertal stage is linked t… | Stress (Amsterdam, Netherlands) 2026-08-16 13:17:42 | Source |
| The impact of (poly)phenol-rich sugarcane extract intervention on mar… Hydrocortisone · PMID 42316869 | Cancer · Sclérose en plaques · Cancer | Immunomodulation · Traitement symptomatique | Publication | PubMed | Voir la publication source Exertional-heat stress (EHS) perturbs gastrointestinal integrity, leading to systemic inflammation that may warrant med… | Journal of the International Society of Sports Nutriti… 2026-08-16 13:17:42 | Source |
| Two-week essential oil inhalation treatment modulates the cortisol aw… Hydrocortisone · PMID 42262170 | Cancer · Sclérose en plaques · Cancer | Traitement symptomatique · Thérapie génique | Publication | PubMed | Voir la publication source We investigated the impact of the inhalation of a blended essential oil aroma on markers of chronic stress in otherwise… | Stress (Amsterdam, Netherlands) 2026-08-16 13:17:42 | Source |
| Coenzyme Q alleviates oxidative stress, inflammation and fibrosis via… Fludrocortisone acetate · PMID 40306396 | Hypertension artérielle | Neuroprotection · Immunomodulation | Publication | PubMed | Voir la publication source Hypertension is one of the most common factors contributing to cardiac remodeling that links to changes in both heart a… | Archives of biochemistry and biophysics 2026-08-16 13:17:41 | Source |
| Feline hypoadrenocorticism: Emerging insights into clinical features,… Fludrocortisone acetate · PMID 42411116 | Cancer | Thérapie génique | Publication | PubMed | Voir la publication source Hypoadrenocorticism in cats is a rare endocrine disorder that should be considered in patients presenting with vague, i… | Schweizer Archiv fur Tierheilkunde 2026-08-16 13:17:41 | Source |
| Process optimization of hot-melt extruded filaments for FDM 3D printi… Fludrocortisone acetate · PMID 41966428 | Cancer | Thérapie génique | Publication | PubMed | Voir la publication source Low-dose oral formulations are often associated with poor dose accuracy (mass and content non-uniformity) and limited r… | International journal of pharmaceutics 2026-08-16 13:17:41 | Source |
| Design, synthesis, and biological evaluation of cytochrome P450 CYP11… Opevesostat · PMID 41628742 | Cancer | À vérifier | Publication | PubMed | Voir la publication source This study addresses drug resistance in castration-resistant prostate cancer by developing novel inhibitors of CYP11A1,… | Bioorganic & medicinal chemistry letters 2026-08-16 13:17:40 | Source |
| Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castra… Opevesostat · PMID 41732008 | Cancer | Thérapie génique | Publication | PubMed | Voir la publication source Treatment options for metastatic castration-resistant prostate cancer (mCRPC) include androgen receptor pathway inhibit… | Future oncology (London, England) 2026-08-16 13:17:40 | Source |
| Global Burden of Elevated LDL-C: Findings From the Global Burden of D… Risk Communication Within Mexican-American Families · PMID 42525403 | Cancer | Ralentissement de la progression | Publication | PubMed | Voir la publication source Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leadin… | JAMA 2026-08-16 13:17:39 | Source |
| Global burden of enteric infectious diseases, diarrhoeal diseases, an… Risk Communication Within Mexican-American Families · PMID 42229499 | Cancer | Ralentissement de la progression | Publication | PubMed | Voir la publication source Enteric infectious diseases claim more than 1 million lives annually and are among the top ten causes of death in child… | The Lancet. Infectious diseases 2026-08-16 13:17:39 | Source |
| Combined effects of electroporation and 100 mGy X-ray on the anticanc… Niraparib · PMID 42229349 | Cancer | À vérifier | Publication | PubMed | Voir la publication source A novel niraparib-derived Schiff base (Sb) ligand and its Pd(II) and Fe(II) complexes were synthesized and comprehensiv… | Bioorganic chemistry 2026-08-16 13:17:38 | Source |
| Design, synthesis and anti-breast cancer activity evaluation of 6,7-d… Niraparib · PMID 41693691 | Cancer | Ralentissement de la progression | Publication | PubMed | Voir la publication source PARP1 inhibitors are FDA-approved for BRCA1/2-mutated breast cancer but show limited efficacy in wild-type cancers and… | Journal of enzyme inhibition and medicinal chemistry 2026-08-16 13:17:38 | Source |
| Combined MEK1/2 and ATR inhibition promotes myeloma cell death throug… M1774 · PMID 39379134 | Cancer | Thérapie génique | Publication | PubMed | Voir la publication source Mechanisms underlying potentiation of the anti-myeloma (MM) activity of ataxia telangiectasia Rad3 (ATR) antagonists by… | British journal of haematology 2026-08-16 13:17:37 | Source |
| Quantitation of Tuvusertib (M1774) in Human Plasma by LC-MS/MS. M1774 · PMID 40485138 | Cancer | Thérapie génique | Publication | PubMed | Voir la publication source Ataxia-telangiectasia and Rad3-related (ATR) protein kinase is an essential regulator of the DNA damage response (DDR)… | Biomedical chromatography : BMC 2026-08-16 13:17:37 | Source |
| The ATR inhibitor tuvusertib (M1774) sensitizes prostate carcinoma to… M1774 · PMID 41417226 | Cancer | Immunomodulation · Thérapie génique | Publication | PubMed | Voir la publication source High levels of replication stress make cancer cells vulnerable to therapies targeting DNA damage response (DDR) protein… | Cancer immunology, immunotherapy : CII 2026-08-16 13:17:37 | Source |
| Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastat… Ficerafusp alfa · PMID 42102329 | Cancer | Ralentissement de la progression | Publication | PubMed | Voir la publication source Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis, particul… | Journal of clinical oncology : official journal of the… 2026-08-16 13:17:34 | Source |
| Immunotherapeutic strategies in HPV-positive and HPV-negative recurre… Ficerafusp alfa · PMID 42144173 | Cancer | À vérifier | Publication | PubMed | Voir la publication source Oropharyngeal squamous cell carcinoma (OPSCC) comprises two biologically distinct entities, HPV-positive and HPV-negati… | Critical reviews in oncology/hematology 2026-08-16 13:17:34 | Source |
Exploration — prudence
Pistes exploratoires 0
Rapprochements mécanistiques et hypothèses de recherche : ils ne constituent pas une preuve d’efficacité ni une recommandation thérapeutique.
Hypothèses non validéesÀ confirmer par des travaux précliniques, cliniques et une revue scientifique indépendante.
| Molécule / élément | Maladie / population | Objectif | Phase / stade | Statut / preuve | Mécanisme / résumé | Source | Détail |
|---|---|---|---|---|---|---|---|
| Aucune piste exploratoire ne correspond aux filtres. | |||||||